Moore Michael 4

What Happened
Michael Moore, President of Viemed Healthcare (VMD), had derivative awards vest/convert and completed related settlements on Jan 17, 2026, and received new equity awards on Jan 19, 2026. On Jan 17 he converted/exercised derivative units that resulted in: 8,548 shares withheld to satisfy tax withholding (reported as F; $7.33/share, $62,657) and 6,735 shares surrendered to the issuer for cash (reported as D; $7.33/share, $49,368). Several derivative conversion/settlement line items are reported with $0 per-share exercise/consideration because they represent the conversion/settlement of RSUs and cash‑settled phantom share units. On Jan 19 he was granted 118,759 RSUs and 29,690 phantom share units (both reported as awards, vesting in three equal annual installments).

Key Details

• Transaction dates: conversions/settlements on 2026-01-17; grants on 2026-01-19. Form filed 2026-01-21.
• Cash amounts reported: tax withholding 8,548 shares × $7.33 = $62,657; shares surrendered 6,735 × $7.33 = $49,368.
• Codes: M = exercise/conversion of derivative; F = tax withholding; D = disposition to issuer; A = award/grant.
• Shares acquired via grant on Jan 19: 118,759 RSUs and 29,690 phantom shares (reported at $0.00 because they are contingent/vested later).
• Footnotes of note:
  • F2: 8,548 shares were withheld by the issuer to satisfy tax obligations from RSU vesting.
  • F4: Phantom shares are cash-settled; settlement reported as simultaneous acquisition of underlying shares and disposition of those shares back to the company for cash.
  • F5/F6/F7/F9: The RSU and phantom awards (including the Jan 19 grants) vest in three equal annual installments beginning on the first anniversary of their grant dates.
• Shares owned after the transactions: not specified in the provided filing.

Context
These transactions primarily reflect routine equity compensation activity (vesting/conversion of RSUs and phantom share units, tax-withholding and cash settlement), not an open-market purchase or voluntary sale. The presence of tax-withholding and issuer surrender/sales indicates cashless/cash-settled processes common with RSU/phantom vesting rather than a deliberate market sale for investment reasons. The filing shows both the settlement of vested derivative awards and the receipt of new awards that will vest over time.